Advertisement
Advertisement
CLLS
Cellectis S.A. - ADR
1.83
USDSponsored
-1.27
-40.97%
Sep 14, 15:59 UTC -4
Closed
Pre-Market
1.58
-0.25
-13.66%
CLLS Earnings Reports
Positive Surprise Ratio
CLLS beat 17 of 24 last estimates.
71%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$18.01M
/-$0.19
Implied change from Q2 26 (Revenue/ EPS)
+160.88%
/-13.64%
Implied change from Q3 25 (Revenue/ EPS)
-51.54%
/-2000.00%
Cellectis S.A. - ADR earnings per share and revenue
On Aug 06, 2026, CLLS reported earnings of -0.22 USD per share (EPS) for Q2 26, beating the estimate of -0.27 USD, resulting in a 20.89% surprise. Revenue reached 6.90 million, compared to an expected 13.62 million, with a -49.32% difference. The market reacted with a +5.39% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 18.01 million USD, implying an decrease of -13.64% EPS, and increase of 160.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Cellectis S.A. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Cellectis S.A. - ADR reported EPS of -$0.22, beating estimates by 20.89%, and revenue of $6.90M, -49.32% below expectations.
How did the market react to Cellectis S.A. - ADR's Q2 2026 earnings?
The stock price moved up 5.39%, changed from $2.69 before the earnings release to $2.83 the day after.
When is Cellectis S.A. - ADR expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Cellectis S.A. - ADR's next earnings report?
Based on 6
analysts, Cellectis S.A. - ADR is expected to report EPS of -$0.19 and revenue of $18.01M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.